Enterprise Value

743.5M

Cash

564M

Avg Qtr Burn

N/A

Short % of Float

16.68%

Insider Ownership

25.67%

Institutional Own.

76.12%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TCER® IMA402 (PRAME) Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

ACTengine® IMA203 GEN1 (PRAME) Details
Cancer, Solid tumor/s, Melanoma

Phase 1b

Data readout

ACTengine® IMA203 GEN2 (PRAME) Details
Melanoma, Cancer, Solid tumor/s

Phase 1b

Update

Phase 1

Data readout

ACTengine IMA201 Details
Solid tumor/s, Cancer

Failed

Discontinued

ACTengine IMA202 Details
Cancer, Solid tumor/s

Failed

Discontinued